⚡ Metabolic 🔴 Essential

HbA1c

A 3-month average of your blood sugar , more reliable than a single glucose reading because it shows the bigger picture over time.

What is HbA1c?

HbA1c , short for Glycated Hemoglobin , is a blood test that measures the percentage of hemoglobin molecules in your red blood cells that have glucose attached to them. Because red blood cells live approximately 90–120 days, HbA1c reflects your average blood sugar over roughly the past 3 months. A single fasting glucose reading is a snapshot in time; HbA1c is the full reel. A person can have a "normal" fasting glucose on any given morning while their HbA1c tells a very different story about what their blood sugar is doing the rest of the day.

HbA1c is the gold standard diagnostic test for diabetes and pre-diabetes, and it is the primary efficacy endpoint in nearly every major GLP-1 receptor agonist clinical trial , including the SUSTAIN series (semaglutide) and SURPASS series (tirzepatide). For GH secretagogue research, elevated HbA1c above 6% combined with elevated fasting insulin signals metabolic stress that warrants clinical attention before initiating any protocol that further affects glucose metabolism.

What do the numbers mean?

Optimal (functional target)
Under 5.3%
Functional medicine target. Suggests minimal glycation burden and strong insulin sensitivity over the prior 3 months.
Standard Normal
Under 5.7%
Standard lab cutoff for the non-diabetic range. Values between 5.3–5.7% may still reflect suboptimal metabolic function in a research context.
Out of Range , Note
5.7–6.4% / ≥6.5%
5.7–6.4% = pre-diabetes range. ≥6.5% = diabetes threshold by ADA criteria. Either warrants clinical evaluation before initiating metabolic research protocols.

HbA1c can be falsely low in conditions affecting red blood cell turnover (hemolytic anemia, recent blood loss) and falsely high in iron deficiency anemia. Lab reference ranges may vary slightly by laboratory and assay method.

Why this marker matters before peptide research.

HbA1c is the definitive metabolic health marker in GLP-1 peptide research. The SUSTAIN trials (semaglutide) and SURPASS trials (tirzepatide) used HbA1c reduction as the primary efficacy endpoint , in these studies, HbA1c reductions of 1.5–2.4% were achieved, with the magnitude of response correlating with baseline HbA1c. For researchers studying these compounds, a pre-protocol HbA1c establishes exactly what metabolic terrain is being worked with and provides the clearest before/after comparison point.

For GH secretagogue protocols, the relationship runs in the other direction: growth hormone is known to impair insulin sensitivity acutely, which can elevate fasting glucose and, over time, HbA1c. This is why HbA1c above 6% combined with elevated fasting insulin is considered a reason for clinical attention before beginning any GH secretagogue protocol , the combination suggests the metabolic system is already under stress, and adding a compound that impairs insulin sensitivity further may compound that stress.

HbA1c is also a stronger predictor of cardiovascular risk than single-point glucose measurements. In longevity research contexts, minimizing glycation burden , keeping HbA1c below 5.3% , is associated with reduced advanced glycation end-product (AGE) accumulation, which has downstream effects on tissue elasticity, vascular health, and biological aging rate.

How to get this test.

Where to order

Available at any major lab , LabCorp, Quest Diagnostics, or through a physician. Direct-to-consumer options include Ulta Lab Tests and LabCorp OnDemand. Typically included in standard metabolic panels and annual physicals.

How to prepare

No fasting required. HbA1c can be drawn any time of day , this is one of its major practical advantages over fasting glucose. There is no need to schedule around meal timing or an overnight fast.

What to ask for

"HbA1c" or "Hemoglobin A1c" or "Glycated Hemoglobin." Order alongside fasting glucose and fasting insulin to build a complete metabolic picture. The three markers together allow HOMA-IR calculation.

Peptides commonly researched in connection with this marker.

Semaglutide HbA1c is the primary efficacy endpoint in semaglutide (GLP-1) research , the SUSTAIN trial series demonstrated reductions of 1.5–1.8% from baseline, with response magnitude correlating with starting HbA1c.
Tirzepatide The dual GIP/GLP-1 agonist SURPASS trials showed HbA1c reductions up to 2.4% , the largest reductions seen in any approved glucose-lowering therapy at time of publication.
Retatrutide The triple agonist (GLP-1/GIP/glucagon) in Phase 2/3 trials uses HbA1c as a co-primary endpoint alongside body weight reduction , early data shows substantial HbA1c lowering.
Ipamorelin GH secretagogues transiently impair insulin sensitivity. Baseline HbA1c above 6% combined with elevated fasting insulin warrants clinical evaluation before initiating any GH secretagogue protocol.
CJC-1295 Same consideration as Ipamorelin , HbA1c is a key safety baseline for any GHRH analog research given the acute glucose-raising effect of GH pulses on hepatic glucose output.
Tesamorelin FDA-approved Tesamorelin clinical trials specifically excluded subjects with HbA1c above 8% , HbA1c is a defined exclusion criterion in formal research designs for this compound.
MOTS-c Mitochondrial-derived peptide with demonstrated glucose-lowering and insulin-sensitizing effects in preclinical models , HbA1c is the relevant longer-term efficacy marker for monitoring any metabolic response.

Goals where this biomarker is most relevant.

Ready to build your baseline?

Use Pepvela's Lab Guide to understand which markers to test first, then use the Peptide Finder to match your biology to research-relevant compounds.

For educational and research purposes only. Not medical advice. Always consult a licensed healthcare provider before making any health decisions.